Technology
Based in Littleton, Massachusetts, Mevion Medical Systems was founded in 2004. The Mevion S250 system received clearance for patient treatment from the Food and Drug Administration (FDA) in 2013 succeeding in the creation of a smaller, lower-cost proton therapy technology, thereby improving accessibility and advancing the treatment of cancer. In 2017 Mevion expanded on their successful launch of the S250 system by releasing the Mevion S250i Hyperscan Proton Therapy system bringing Pencil Beam Delivery technology to Proton Therapy and in 2022 Mevion made Compact Proton Therapy even smaller with the introduction of the Mevion S250-FIT system currently under review for FDA Clearance
Since the introduction of the S250 family of Proton Therapy Systems versions of the S250 and S250i have been delivered to over 20 cancer centers worldwide including 7 NCI Designated Comprehensive Cancer Centers, as well as Major Healthcare Systems and Private Practice Cancer Centers with more centers currently under development.
Treatment Room 360 VR
[Pan using left mouse button, and zoom in or out using scroll wheel]
Mevion S250i
Treatment Room and Gantry Cutaway
MEVION Treatment Room Animation
MEVION Accelerator
MEVION Hyperscan Cutaway
The Mevion S250i with Hyperscan and Adaptive Aperture™ delivers high quality, robust pencil beam scanning for Intensity Modulated Proton Therapy. The patented Adaptive Aperture can automatically tailor beam characteristics to match a tumor at any spot and depth. The benefits are a sharper penumbra that eliminates dose uncertainty and delivers less radiation to healthy tissues.
It is ideal for treating shallow pediatric or brain tumors, where small spot sizes are difficult to achieve. The Adaptive Aperture is a ground-breaking, low profile Multileaf Collimator (MLC) system specifically designed for pencil beam scanning. The system uses a fully automated adaptive aperture that generates layer-by-layer specific beam collimation and blocking identical to conventional proton therapy apertures.
Robustness Lowers Clinical Uncertainty: 10-50x faster scanning and 2-3x sharper compared with non-IMPT treatments.
Clinical optimization: Image quality and robotic precision merge for < 1 mm IGRT positioning with in-room 3D imaging.
Sharper Spot Size Collimation: 1 to 3 mm collimated spot sizes (sigma equivalent) for all energies: 0-32 cm depth.
Faster Volumetric Scanning: Scan a typical lung tumor in less than 2 seconds.
Visit the Mevion website and learn more about this exciting company and technology.
